Anti-VEGF thwarts retinal nonperfusion progression in eyes with BRVO, CRVO

Ranibizumab reduced retinal nonperfusion in eyes with macular edema stemming from retinal vein occlusion, according to a study.Data were culled from the BRAVO and CRUISE studies, which evaluated the safety and efficacy of Lucentis (ranibizumab, Genentech) intraocular injections in patients with macular edema following retinal vein occlusion.